BCDA - BioCardia, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BCDA

BIOCARDIA, INC.

NASDAQ

$1.06

▼ DOWN 2.75% (-0.03)

KEY STATISTICS

Market Cap$15.78 M

52w High$1.80

52w Low$0.75

Dividend Yield—

Frequency—

P/E-1.66

Volume162.40K

Shares Out.14.88M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Peter A. Altman

COMPENSATION 2026

Salary$493,388

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$493,388

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 13, 1996

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.—

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2024-05-30	Reverse	1:15
2019-06-06	Reverse	1:9
2017-11-03	Reverse	1:12
2008-03-20	Reverse	1:10
2008-03-14	Reverse	1:10
2004-01-06	Forward	6:1
2001-08-23	Reverse	1:3

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

VXF

0.00%

69.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED

2.72%

HOLDERS

TOP 8 OF 14 · RANKED BY POSITION SIZE

Geode Capital Management, LLC

94.3K sh

$114.09K

Ladenburg Thalmann Financial Services Inc.

Susquehanna International Group, Llp

PRICE

$1.06 ▼ DOWN 2.75% (−$0.03)

OVERLAYS

About BioCardia, Inc.

https://www.biocardia.com ↗

BioCardia, Inc. is a clinical-stage regenerative medicine company developing cell-based therapies and delivery systems for cardiovascular and pulmonary diseases, including its lead CardiAMP Cell Therapy System for heart failure.

INDUSTRY

Biotechnology

A PRODUCT BIOCARDIA, INC. IS KNOWN FOR

Helix Transendocardial Delivery System

BioCardia's biotherapeutic delivery catheter enables minimally invasive, targeted delivery of biologics to the heart, serving as a key technology for their cell therapy platforms and currently under FDA review.

COMPETITORS

COMPETITOR

BioCardia in 2025

SENTIMENT: + POSITIVE

REGULATORY · DECEMBER 2025

BioCardia's CardiAMP Cell Therapy Advances to Formal Clinical Consultation with Japan's PMDA for Heart Failure Treatment

In December 2025, BioCardia announced the completion of a third successful preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) for its CardiAMP cell therapy. This allowed the company to advance to a formal clinical consultation, a critical step toward seeking regulatory approval for their heart failure treatment in the Japanese market based on existing clinical data.

MARKET EXPANSION · THROUGHOUT 2025 · IN PROGRESS

BioCardia Accelerates Push for First-Ever Market Approvals with Dual Regulatory Submissions in U.S. and Japan for CardiAMP Cell Therapy

In 2025, BioCardia's leadership made a decisive strategic shift to aggressively pursue regulatory approval for its lead product, the CardiAMP Cell Therapy System, in both the United States and Japan. This represents the company's most significant move towards commercialization, transitioning from a purely clinical-stage entity to one on the cusp of market entry.

Latest News

GLOBENEWSWIRE · OCT 7, 2026

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the upcoming presentation of a scientific poster entitled “Cardiac Delivery of Autologous Minimally Processed Cell Therapy in HFrEF: Multicenter, Double Blind RCT (CardiAMP HF II)” at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.

READ ARTICLE

EARLIER COVERAGE

GLOBENEWSWIRE · OCT 1, 2026

BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic and diagnostic agent delivery to the heart.

READ ARTICLE